(Q46965896)

26 December 2017

title

Neuropsychiatric profiles of patients with juvenile myoclonic epilepsy treated with valproate or topiramate (English)

1 reference

26 December 2017

juvenile myoclonic epilepsy

1 reference

1 reference

based on heuristic

inferred from title

author name string

Gerardo M de Araujo Filho

1

1 reference

26 December 2017

Tatiana F Pascalicchio

2

1 reference

26 December 2017

Katia Lin

3

1 reference

26 December 2017

Patrícia S Sousa

4

1 reference

26 December 2017

Elza M T Yacubian

5

1 reference

26 December 2017

publication date

28 February 2006

1 reference

26 December 2017

published in

Epilepsy Behavior

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

606-609

1 reference

26 December 2017

Characteristics of valproic acid resistant juvenile myoclonic epilepsy.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Clinical factors of drug resistance in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Effects of topiramate on cognitive function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Differential cognitive and behavioral effects of topiramate and valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

The importance of being seizure free: topiramate and psychopathology in epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Comprehensive review of the psychiatric uses of valproate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Proposal for revised classification of epilepsies and epileptic syndromes. Commission on Classification and Terminology of the International League Against Epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Comparative cognitive effects of phenobarbital, phenytoin, and valproate in healthy adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Topiramate and word-finding difficulties in patients with epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Reversible language regression as an adverse effect of topiramate treatment in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

Interictal mood and personality disorders in temporal lobe epilepsy and juvenile myoclonic epilepsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YEBEH.2006.01.016

10.1016/J.YEBEH.2006.01.016

7 January 2021

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

16504593

1 reference

26 December 2017